Resource Library

TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is...

Now, more than ever, sponsors and CROs need to prioritize including patient engagement in their study builds from the ground-up. This involves defining processes to remove barriers for access, increasing awareness and education for clinical trials, and creating effective exchanges between patients and their clinicians.

When your trials rely on an investigational product (IP), your study timeline, budget, and overall success are closely tied to having the right product available at the right time and site. Once randomization is added in, sponsors can struggle to maintain an increasingly complex supply chain. Achieve operational efficiency with RTSM.

Are your clinical trials equipped for a modern world? Prior to 2020, the answer was likely not very much.

Disruptions due to COVID-19 paired with a slew of new guidance from regulatory bodies has catapulted the clinical trial industry into a period of digital transformation.1 More sponsors and CROs are beginning to adopt decentralized solutions and embrace digital workflows, yet informed consent continues to rely heavily on paper-based processes. Lots and lots of paper.

Hybrid clinical trial models aren’t new, but they have grown from a novelty to a necessity over the past decade.1 While the benefits of hybrid trials cannot be overstated, many decision makers still view it as a temporary measure. Others remain weary or unsure of how to take the first steps into hybrid decentralized studies, let alone embrace it on a wide scale.